Alpha-terpineol

Other Names

(8S)-p-menth-1-en-8-ol(R)-2-(4-Methyl-3-cyclohexenyl)isopropanol(R)-p-Menth-1-en-8-ol(S)-(-)-α-Terpineol(S)-p-Menth-1-en-8-ol1-alpha-terpineol1-Menthene-8-ol1-p-Menthen-8-ol2-(4-Methyl-3-cyclohexen-1-yl)-2-propanol2-(4-Methyl-3-cyclohexenyl)-2-propanol2-(4-methylcyclohex-3-en-1-yl)propan-2-ol2-[(1S)-4-Methyl-1-cyclohex-3-enyl]propan-2-ol3-Cyclohexene-1-methanol, α,α,4-trimethyl-3-Cyclohexene-1-methanol, α,α,4-trimethyl-, (1S)-CarvomenthenolD-alpha-terpineoldl-alpha-terpineolDL-α-TerpineolFEMA 3045L-alpha-terpineolL-α-TerpineolLilacinp-Menth-1-en-8-olTerpene alcoholTerpineolTerpineol schlechthinTerpineol, α[1S,(-)]-α,α,4-Trimethyl-3-cyclohexene-1-methanolα,α,4-Trimethyl-3-cyclohexene-1-methanolα-Terpineolα-Terpinol

Synopsis

Alpha-Terpineol: A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Classification

Alpha-terpineol is a naturally occurring organic compound classified as a monoterpene alcohol. Its CAS number is 98-55-5, and it is a tertiary monoterpenoid alcohol widely and commonly used in the flavors and fragrances industry for its sensory properties. Its empirical formula is C₁₀H₁₈O and its molecular weight is 154.25. It carries the EC (EINECS) number 233-986-8. It is also known by the synonyms Menthen-8-ol; 1-p-Menthen-8-ol; alpha-terpinenol; and 2-(4-methylcyclohex-3-enyl)propan-2-ol, among others.

α-Terpineol is a terpene alcohol found in natural oils such as pine oil and petitgrain (the oil from the bitter orange tree). It is the most common of four structural isomers; the others are β-, γ-, and 4-terpineol. It should not be confused with terpinol, the hydrate of terpin, which is a terpene diol.

α-Terpineol is a racemic mixture of (R)-(+)- and (S)-(–)-enantiomers. Both are found in nature; but the commercial article, which is usually synthesized from α-pinene, is the racemate. Whilst both enantiomers of α-terpineol exhibit a floral lilac aroma, the laevo form (–)-α-terpineol is reportedly more terpenic.

Physical Properties and Aroma Profile

Alpha-terpineol typically presents as a colourless transparent liquid with a distinctive lilac and pine aroma. Its aroma has been described as "pine, terpenic, lilac, citrus, woody, floral, resinous, cooling, lemon, lime." It has a lilac odor and sweet smell reminiscent of peach, with an aroma threshold of 280–350 ppb.

Historical Isolation

In 1903, German chemists H. Waldbaum and O. Hüthig isolated the (+)-stereoisomer from petitgrain. Four years later, J. E. Teeple of New York City separated its enantiomer from long-leaf pine oil.

2. Natural Sources and Botanical Origins

Alpha-terpineol has been reported found in over 260 natural sources, including apple, apple juice, apricot, sweet and sour cherry, citrus peel oils and juices, orange, and lemon. Terpineols have been isolated from a variety of sources such as cardamom, cajuput oil, pine oil, and petitgrain oil.

The l-form is found in Satureia montana, lavandin, cajeput, lime, lemon, cinnamon leaves, and the distillates from Pinaceae (with the exception of Pinus sylvestris, which contains d-terpineol together with a racemic form); likewise in Nectandra elaiophora (wood) and petitgrain bigarade. The racemic form is found in cajenne linalool, Thymus caespititius, cajeput, and Eucalyptus globulus.

It is a water-soluble component of Melaleuca alternifolia Cheel, the tea tree. Alpha-terpineol is found at 5–10% in the essential oils of distilled lime, palo santo, tea tree, and Eucalyptus radiata. It is also found, in very much smaller amounts, in apples, blueberries, and limes.

α-Terpineol is one of the two most abundant aroma constituents of lapsang souchong tea; the α-terpineol originates in the pine smoke used to dry the tea. (+)-α-Terpineol is a chemical constituent of skullcap. α-Terpineol is one of the major monoterpenol components of the cultivar Gewürztraminer and other aroma-rich grape varieties.

3. Production and Common Forms

Alpha-terpineol is present in different natural sources, but its production is mostly based on chemical hydration using α-pinene or turpentine. Moreover, many bioprocesses for the microbial production of α-terpineol via biotransformation of monoterpenes (limonene, α- and β-pinenes) are also available in the literature.

Although it is naturally occurring, terpineol is commonly manufactured from alpha-pinene, which is hydrated in the presence of sulfuric acid. Industrially, alpha-terpineol is primarily produced by hydrating alpha-pinene or dehydrating terpin hydrate, with the synthetic process often resulting in isomers such as β-terpineol and γ-terpineol.

The reported food usages for α-terpineol, usually in a range of 10–20 ppm, include baked goods, chewing gum, condiments, dairy products, candies, and beverages. Its annual consumption is estimated to be approximately 9.2 tons, which represents an individual intake of 17.2 μg/kg/day in the US. In the flavor industry, alpha-terpineol carries FEMA number 3049 and is designated as GRAS (Generally Recognized As Safe) for use as a flavoring ingredient.

Common commercial and supplementary forms of alpha-terpineol include:

Isolated and purified monoterpene alcohol (neat liquid), typically ≥95% or ≥98% purity
As a major constituent within steam-distilled essential oils (pine oil, tea tree oil, eucalyptus oil, petitgrain oil)
Incorporated into topical formulations, including ointments and creams, where it also serves as a skin penetration enhancer
As a food-grade flavoring additive in the ranges noted above
Occasionally found as a volatile component in urine, reflecting its metabolic processing after consumption or exposure.

4. Traditional and Historical Use

In folk medicine, as well as in phytotherapy, essential oils have been utilized as therapeutic agents to treat several diseases. Alpha-terpineol was not typically isolated and administered as a pure compound in traditional practice; rather, it reached users as a constituent of the plant oils in which it occurs. This phytochemical has been recognized as a potent ingredient in folk medicine as well as in aromatherapy.

Historically, alpha-terpineol has held a valued place in traditional medicine and herbal remedies across different cultures. Its pleasant lilac-like aroma made it popular not only in perfumery but also as a therapeutic agent. Records from European herbalism and traditional Chinese medicine highlight its use for its soothing and disinfectant properties.

Alpha-terpineol was commonly utilized to support respiratory health, being included in inhalations and chest rubs to ease symptoms of colds, coughs, and congestion. Its mild antimicrobial and anti-inflammatory actions were believed to help in wound care and skin irritations.

It was frequently used to treat several diseases, such as gastroenteritis, respiratory infections, cardiovascular problems, diabetes, menstrual pain, and headaches — though this refers specifically to its presence within broader plant oils and preparations used by traditional practitioners, not as a purified ingredient.

5. Key Active Constituents and Mechanisms of Action

Alpha-terpineol is itself the bioactive entity under investigation in most preclinical work. In recent years, α-terpineol has been increasingly associated with some biological effects, such as anti-inflammatory, antioxidant, antiproliferative, and antimicrobial activity. Multiple distinct molecular mechanisms have been proposed across different experimental systems.

Antimicrobial Mechanisms

Study has demonstrated that its antibacterial (bactericidal) effect originates from its destroying effect on the cell wall and cell membrane of bacteria. Other studies on the mode of action of α-terpineol have shown that it can act by blocking DNA, RNA, proteins, polysaccharide synthesis, ATP production, or the tricarboxylic acid cycle.

In antifungal applications, two components of tea tree oil (Melaleuca alternifolia oil), α-terpineol and terpene-4-alcohol, showed higher antifungal effects than the whole oil, of which α-terpineol caused the worst leakage of cytoplasm and most serious hyphae distortions and spore disruptions.

Anti-inflammatory and Analgesic Mechanisms

Alpha-terpineol is a monoterpenoid alcohol with inhibitory effect on inflammatory cytokines. In the context of anticancer activity, alpha terpineol was proposed as an NF-κB inhibitor, confirmed by dose-dependent inhibition of NF-κB translocation and activity, and by the down-regulation of the expression of several NF-κB-related genes such as IL-1β and IL1R1.

α-Terpineol has been shown to reduce the compound action potential (CAP) in rat sciatic nerve, indicating an inhibitory effect on voltage-dependent sodium channels.

Cardiovascular Mechanisms

Using combined functional and biochemical approaches, researchers were able to demonstrate that alpha-terpineol-induced hypotension and vasorelaxation are mediated, at least in part, by the endothelium, most likely via NO release and activation of the NO-cGMP pathway. Furthermore, in a rabbit aortic endothelial cell line, α-terpineol induced concentration-dependent increases in nitric oxide (NO) levels.

Central Nervous System Mechanisms

The anxiolytic and anticonvulsant effects appear to be related to the GABAergic system, probably at the receptor subtypes that mediate the effects of benzodiazepines, generating anxiolytic activity. The sedative effect seems to be involved with other signaling pathways. It is hypothesized that terpineol could interact with different targets in the central nervous system (CNS), including receptors that are related to the pathogenesis of depression, such as serotonergic, dopaminergic, and adenosinergic receptors. Terpineol showed a coherent predicted binding mode mainly against CB1 and CB2 receptors and also against the D2 receptor during docking modeling analyses.

Hepatic Lipid Metabolism

One study showed that α-terpineol induces fatty liver via the AMP-activated protein kinase (AMPK)-mTOR-sterol regulatory element-binding protein-1 (SREBP-1) pathway. Alpha-terpineol suppressed AMPK phosphorylation, and increased p70S6 kinase phosphorylation and SREBP-1 activation. This mechanism is discussed further under Safety Considerations below.

6. Scientific Evidence by Area of Use

6.1 Antimicrobial and Antifungal Activity

Alpha-terpineol has exhibited strong and broad antimicrobial activity against fungi, bacteria, and virus in study settings. α-Terpineol and terpinen-4-ol are effective bacterial inhibitors with a broad bacterial spectrum, including against Staphylococcus aureus, Streptococcus agalactiae, Bacillus coagulans, and Micrococcus luteus.

A study published in the Journal of Applied Microbiology (PMID 30614164) investigated the antifungal mechanisms of α-terpineol against Aspergillus ochraceus in postharvest grapes. Compositions in tea tree oil were analyzed by gas chromatography-mass spectrometry. The inhibitory effects of the oil and its main constituents against A. ochraceus were compared by scanning electron microscopy, transmission electron microscopy, and metabolic analysis. Two components — α-terpineol and terpene-4-alcohol — showed higher antifungal effects than the whole oil, of which α-terpineol caused the worst leakage of cytoplasm and most serious hyphae distortions and spore disruptions. This was a laboratory (in vitro) study; no human trials are available for this application.

Evidence strength: Predominantly in vitro and animal-based. No human clinical trials are available for antimicrobial indications. Evidence is preliminary and mechanistic.

6.2 Analgesic and Antinociceptive Activity

α-Terpineol possesses antinociceptive effect in the formalin test and remarkably decreases pain response, especially in the second phase of the formalin test.

A PMC study (PMC7043874) investigated α-terpineol in a rat model of neuropathic pain. Alpha-terpineol is a monoterpenoid alcohol with inhibitory effect on inflammatory cytokines. The study evaluated the effect of α-terpineol on neuropathic pain in rats. The chronic constriction injury (CCI) model was utilized. Rats were randomly divided into control, sham, α-terpineol, and gabapentin groups. α-Terpineol at doses of 25, 50, and 100 mg/kg, and gabapentin at 100 mg/kg, were administered intraperitoneally once daily for 14 days post-CCI. Behavioral tests including Von Frey, acetone, and Hargreaves tests were used to assess mechanical allodynia, cold allodynia, and hyperalgesia.

A study published in Basic and Clinical Pharmacology and Toxicology (PMID 29902764) investigated cancer-associated pain. α-Terpineol is present in a wide range of essential oils of the genus Eucalyptus, with recognized potential for analgesic biological effects. The study aimed to investigate the effect of α-terpineol on cancer pain induced by sarcoma 180 in Swiss mice. Results showed that α-terpineol significantly reduced mechanical hyperalgesia and spontaneous and palpation-induced nociception, and improved paw use without reducing tumor growth or grip strength.

Regarding morphine tolerance, a study referenced in PMC literature (Parvardeh et al., Iran J Basic Med Sci, 2016) reported that α-terpineol attenuated dependence and tolerance to the analgesic effect of morphine.

Evidence strength: All evidence is animal (rodent) based. No human clinical trials exist for analgesic indications. Evidence is promising at the preclinical level but cannot be extrapolated to human efficacy.

6.3 Anti-inflammatory Activity

α-Terpineol has been evaluated in medical application fields, since some biological properties other than aroma, such as antioxidant, anti-inflammatory, antiproliferative, antimicrobial, and analgesic effects, have been attributed to this compound. The anti-inflammatory activity is linked primarily to NF-κB pathway inhibition and suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). These findings derive entirely from in vitro cell studies and animal models.

Evidence strength: Preclinical only (in vitro and animal). No human clinical anti-inflammatory trials have been conducted.

6.4 Potential Anticancer Activity

A study published in Anticancer Research (2010) investigated the anticancer potential of alpha-terpineol as a bioactive component of Salvia libanotica essential oil. Alpha terpineol is a bioactive component of Salvia libanotica essential oil extract and has shown antitumour activity. The cytotoxicity of alpha terpineol towards different tumour cell lines was evaluated in vitro. Mechanistic characterization was performed using analysis of drug activity in a cell line panel and drug-induced gene expression perturbation using the connectivity map approach. The small cell lung carcinoma was the cell line most sensitive to alpha terpineol. The results suggest that alpha terpineol inhibits the growth of tumour cells through a mechanism that involves inhibition of the NF-κB pathway.

A 2025 PMC study (PMC12858878) examined α-terpineol's effect on melanoma cells. α-Terpineol, a key component of tea tree oil, exhibits diverse pharmacological effects, including antimicrobial, antifungal, anti-inflammatory, antiviral, and antioxidant activities. Emerging research suggests its potential as an anticancer agent by influencing tumor cell proliferation and apoptosis. Although previous studies have shown α-terpineol's antitumor effects in various cancer cell lines, its role and regulatory mechanisms in melanoma are not well understood.

A toxicogenetic study (Drug and Chemical Toxicology, 2023–2024) assessed cytotoxicity. The findings indicate that alpha-terpineol has cytotoxic potential by cytogenetic and molecular mechanisms associated with apoptosis and probable target effects against melanoma cells.

Evidence strength: All anticancer evidence is in vitro (cell culture) or early-stage preclinical. No human or animal tumor efficacy trials exist. These results are hypothesis-generating only and should not be interpreted as evidence of clinical anticancer activity.

6.5 Cardiovascular Effects

A study published in Clinical and Experimental Pharmacology and Physiology (PMID 20374260) investigated cardiovascular effects in rats. In normotensive rats, administration of alpha-terpineol at doses of 1, 5, 10, 20, and 30 mg/kg intravenously produced a dose-dependent hypotension (−10, −20, −39, −52, and −57 mmHg, respectively) followed by tachycardia. Alpha-terpineol-induced hypotension and vasorelaxation are mediated, at least in part, by the endothelium, most likely via NO release and activation of the NO-cGMP pathway.

Evidence strength: Animal study only (rats). No human cardiovascular trials are available. The route of administration (intravenous) in this study does not reflect typical human exposure.

6.6 Gastroprotective Activity

A PMC study (PMC3304384) evaluated α-terpineol in two gastric ulcer models in rats. The results suggest that α-terpineol presents gastroprotective action which does not involve either an increase in the synthesis of endogenous prostaglandin or a decrease in gastric acid secretion. It is possible that the gastroprotective activity of α-terpineol occurs by cytoprotective mechanisms. However, the clinical potential of cytoprotective compounds for the treatment of ulcers is still poorly explored. The results show that the monoterpene α-terpineol presents gastroprotective activity in two widely used models for the evaluation of antiulcerogenic drugs.

Evidence strength: Preclinical animal study only. No human gastrointestinal clinical trials are available.

6.7 Central Nervous System: Anticonvulsant, Anxiolytic, Sedative, and Antidepressant Activity

Several pharmacological effects have been described for α-terpineol, including anticonvulsant and neuroprotective activity. The anticonvulsant activity was investigated in a 2007 paper by de Sousa et al. published in Pharmaceutical Biology.

A preclinical study on antidepressant potential found that animals that received alpha-terpineol had reduced immobility time in the Forced Swimming Test and Tail Suspension Test, compared to the other groups. In the Open Field Test and Rota-rod tests, the mice showed good exploratory activity and motor coordination.

A PMC study (PMC7280984) using an inflammatory model of depression (LPS-induced) found that terpineol has shown immunomodulatory and neuroprotective effects. A single lipopolysaccharide (LPS) injection was used to induce a depressive-like effect, and terpineol was assessed in the tail suspension test and the splash test. The study investigated the antidepressant-like mechanism of action of terpineol using molecular and pharmacological approaches. Terpineol showed a coherent predicted binding mode mainly against CB1 and CB2 receptors and also against the D2 receptor during docking modeling analyses.

A separate study cited in the neuropathic pain literature (Moghimi et al., Iran J Basic Med Sci, 2016) specifically investigated neuroprotection: Moghimi et al. described a protective effect of α-terpineol against impairment of hippocampal synaptic plasticity and spatial memory following transient cerebral ischemia in rats, published in Iran J Basic Med Sci (2016).

Evidence strength: All CNS evidence derives from rodent models. No human trials exist for any neurological or psychiatric indication. Evidence is preclinical.

6.8 Antidiarrheal Activity

Alpha-terpineol has a role in pharmacological applications related to diarrhea. This was specifically examined in a 2019 preclinical study (Dos Santos Negreiros et al., Biomed Pharmacother 110:631–640, 2019) demonstrating antidiarrheal activity of α-terpineol in mice.

Evidence strength: Animal study only. No human trials available.

6.9 Skin Penetration Enhancement

Terpenes as penetration enhancers significantly increase the percutaneous permeation of lipophilic small-molecule drugs through intact skin by 1.06–256.80-fold when co-administered. Higher enhancement ratios were recorded for nerolidol, carvacrol, borneol, terpineol, limonene, menthone, linalool, pulegone, and menthol. Terpenes are among the penetration enhancers utilized in formulations and are categorized by regulatory bodies as generally recognized as safe (GRAS).

Evidence strength: The penetration-enhancing effect is supported by multiple in vitro and ex vivo permeation studies. This is arguably the most practically established application in pharmaceutical formulation science, though data are still largely derived from laboratory membrane experiments rather than human clinical endpoints.

7. Body Systems Associated with Alpha-Terpineol Research

Nervous system: Anticonvulsant activity, sedation, anxiolysis, antidepressant-like behavior, neuroprotection after ischemia, attenuation of morphine tolerance
Musculoskeletal/pain system: Antinociceptive (formalin model), neuropathic pain, cancer-associated pain, mechanical hyperalgesia
Cardiovascular system: Hypotensive and vasorelaxant effects via NO-cGMP pathway
Gastrointestinal system: Gastroprotection (ulcer models), antidiarrheal activity
Immune/inflammatory system: NF-κB inhibition, cytokine suppression, antioxidant activity
Integumentary/dermatological system: Skin penetration enhancement, antimicrobial properties in topical formulations
Oncology (preclinical): Cytotoxicity to cancer cell lines, apoptosis induction in melanoma
Hepatic system: Induction of lipid accumulation (adverse, at high doses in animals)

8. Dosage Forms and Dosages Reported in Studies

No established human therapeutic dosage for alpha-terpineol as a dietary supplement exists in the peer-reviewed literature. All dosages described below were reported in preclinical (animal) studies:

Neuropathic pain (rat, intraperitoneal): α-Terpineol was administered at 25, 50, and 100 mg/kg intraperitoneally, once daily for 14 days post-chronic constriction injury (CCI).
Cardiovascular (rat, intravenous): Alpha-terpineol was administered at 1, 5, 10, 20, and 30 mg/kg intravenously, producing dose-dependent hypotension.
Hepatic lipid effects (mouse, oral): α-Terpineol oral administration to mice for 2 weeks led to decreased AMPK phosphorylation and increased SREBP-1 activation in the liver, followed by hepatic lipid accumulation. The specific oral dose range was not stated in the available abstract text.
Reproductive toxicity (rat, oral gavage): Six male and female Wistar rats per group received α-terpineol through gavage at doses of 0, 75, 150, and 300 mg/kg/day. The study revealed changes including body weight gain inhibition, food consumption changes, azoospermia, decreased testosterone levels, as well as histopathological variations in testis and epididymis.
Food use (human, indirect): The reported food usages for α-terpineol are usually in a range of 10–20 ppm in baked goods, chewing gum, condiments, dairy products, candies, and beverages.

9. Safety Considerations

General Toxicological Profile and Regulatory Status

The oral LD₅₀ for α-terpineol in the rat has been reported as 4,300 mg/kg. No agency — including IARC, NTP, ACGIH, OSHA, or Mexico — has listed α-terpineol as a carcinogen.

Based on the low toxicity of α-terpineol in available studies, the US EPA concluded that there are no toxicological endpoints of concern for the US population, including infants and children. The EPA determined that there is a reasonable certainty that no harm to the general population or any population subgroup, including infants and children, will result from aggregate exposure to α-terpineol residues.

Pharmacological doses of α-terpineol are described as free of toxic effects in preclinical contexts where effects of therapeutic interest have been observed; however, this characterization is specific to the dose ranges studied and does not account for the reproductive and hepatic effects described at higher doses.

Mutagenicity

A RIFM-related analysis reported that no increases in the mean number of revertant colonies were observed at any tested dose in the presence or absence of metabolic activation (S9). Under the conditions of the study, α-terpineol acetate was not mutagenic in the Ames test.

Reproductive and Developmental Toxicity

A study examining reproductive toxicity at high doses found significant safety signals. At doses of 0, 75, 150, and 300 mg/kg/day administered by gavage to Wistar rats, the study revealed changes including body weight gain inhibition, food consumption changes, azoospermia, decreased testosterone levels, as well as histopathological variations in testis and epididymis. This exposure also led to significantly decreased serum T4 levels in both adult males and dams at the dose range of 150 and 300 mg/kg/day without affecting TSH concentrations. The study showed that α-terpineol induced reproductive toxicities in male rats. These findings were observed at doses substantially above those encountered in typical food use (10–20 ppm), but they underscore the importance of not extrapolating GRAS food-additive status to high-dose supplement use.

Hepatic Effects

A study showed that α-terpineol induces fatty liver via the AMPK-mTOR-SREBP-1 pathway. α-Terpineol-treated hepatocytes had significantly increased neutral lipid accumulation. This is an adverse pharmacological observation from animal and cell-based research that warrants caution regarding high-dose or chronic supplemental exposures.

Skin and Eye Irritation

Safety data sheet classifications for alpha-terpineol indicate Category 2 for skin corrosion/irritation and Category 2 for serious eye damage/irritation. These classifications apply to the undiluted substance as handled industrially.

Genotoxicity Concerns at High Concentrations

A preclinical toxicogenetic study noted that alpha-terpineol was cytotoxic to meristematic cells, revealing inhibition of cellular division and mutagenic action by formation of bridges and delayed anaphases. The compound increased damage index and frequency of damage corroborated by the presence of micronuclei, bridges, and nuclear buds at 500 μg/mL. However, it caused neither hemolysis, oxidative damage on S. cerevisiae, nor cell death in normal fibroblasts. These effects were observed at high concentrations in cell-based assays and do not directly predict human risk at typical use levels.

GRAS Status and Food-Level Exposure

Alpha-terpineol carries FEMA number 3049 and is designated as GRAS for use as a flavoring ingredient. The FEMA GRAS assessment has been reviewed against the background of food consumption levels. A JECFA review (WHO Food Additives Series No. 42, 1999) included alicyclic tertiary alcohols such as α-terpineol in its safety evaluation. The Flavor and Extract Manufacturers Association (FEMA) listing pertains specifically to flavoring use and does not constitute approval of high-dose supplemental use.

Overall Evidence Gaps

It is important to emphasize that no human clinical trials have been conducted specifically on alpha-terpineol as a dietary supplement for any health indication. All pharmacological evidence — for pain, inflammation, antimicrobial activity, cardiovascular effects, neurological effects, and gastroprotection — originates from in vitro cell studies or rodent experiments. Evidence for benefit in humans cannot be inferred directly from these data. The reproductive toxicity signals in rodents at 150–300 mg/kg/day, the hepatic lipid-accumulation findings, and the high-concentration genotoxic signals in cell studies represent open safety questions that have not been resolved by clinical research.

References

Health Conditions

Health conditions that Alpha-terpineol may help support.

No conditions available.

Body Systems

Body systems that Alpha-terpineol may help support.

No body systems available.